RT Journal Article
SR Electronic
T1 Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 121
OP 127
DO 10.1183/09031936.06.00131304
VO 27
IS 1
A1 J. Börgel
A1 B. M. Sanner
A1 A. Bittlinsky
A1 F. Keskin
A1 N. K. Bartels
A1 N. Buechner
A1 A. Huesing
A1 L. C. Rump
A1 A. Mügge
YR 2006
UL http://erj.ersjournals.com/content/27/1/121.abstract
AB Recent studies suggest an association of obstructive sleep apnoea (OSA) with cardiovascular risk factors, such as dyslipidaemia. The present study analyses the effects of OSA and its therapy on serum lipid concentrations in 470 OSA patients in a single centre study. Multivariate regression showed a significant association between the apnoea–hypopnoea index and high-density lipoprotein cholesterol (HDL-C) serum levels (n = 366), independent of age, sex, body mass index, diabetes and lipid lowering medication. There were no independent associations with total cholesterol, triglyceride and low-density lipoprotein cholesterol serum levels. During follow-up (6 months) with effective bilevel or continuous positive airway pressure therapy in 127 patients (lipoproteins: n = 86) without change in their lipid lowering therapy, the mean HDL-C serum level increased significantly by 5.8% from 46.9±15.8 to 49.6±15.3 mg·dL−1 (mean±SD). An independent relationship was found between the change of apnoea–hypopnoea index and the change of high-density lipoprotein cholesterol or triglycerides, respectively. All patients with abnormal serum lipid/lipoprotein levels improved significantly under bilevel or continuous positive airway pressure therapy. This study demonstrates an influence of obstructive sleep apnoea and its therapy on high-density lipoprotein cholesterol levels.